Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix 10 vs 4 Months in Recurrent Prostate Cancer
NCT01512472Phase 4Terminated
- Sponsor
- Canadian Urology Research Consortium
- Start
- Jan 2012
- Primary completion
- Jan 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of degarelix in prostate cancer (PCa) (2 arms), sponsored by Canadian Urology Research Consortium. Primary endpoint: Length of the off treatment interval at 15 months. Started Jan 2012; status: terminated.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01512472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01512472.